TGTX
TG Therapeutics (TGTX)
$99
About TG Therapeutics (TGTX)
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Details
Daily high
$43.15
Daily low
$41.19
Price at open
$41.62
52 Week High
$43.15
52 Week Low
$12.93
Market cap
6.8B
Dividend yield
0.00%
Volume
4.7M
Avg. volume
3.7M
P/E ratio
307.95
TG Therapeutics News
Details
Daily high
$43.15
Daily low
$41.19
Price at open
$41.62
52 Week High
$43.15
52 Week Low
$12.93
Market cap
6.8B
Dividend yield
0.00%
Volume
4.7M
Avg. volume
3.7M
P/E ratio
307.95